Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Uveal Melanoma × Dacarbazine × Clear all

Phase

Phase 2 5 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 25 Hodgkin Disease 20 Lymphoma 9 Skin Neoplasms 4 Neoplasm Metastasis 4 Sarcoma 3 Leiomyosarcoma 3 Neuroblastoma 2 Neoplasms 2 Uveal Melanoma 1 Skin Diseases 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Melanoma, Cutaneous Malignant 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Liposarcoma 1

Interventions

Melphalan 3 tebentafusp 1 sargramostim 1 fotemustine 1 aflibercept 1 Ranibizumab 1 Nivolumab 1 Neoadjuvant Therapy 1 Melatonin 1 MART-1 Antigen 1 Ipilimumab 1 Eye Enucleation 1 Dacarbazine 1 Colony-Stimulating Factors 1 Chemotherapy, Cancer, Regional Perfusion 1 Brachytherapy 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01974752 2017-01-05

SUMIT

AstraZeneca

Phase 3 Completed

152 enrolled 14 charts

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡